

Kristin Klemmetsby Solli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9394271/publications.pdf>

Version: 2024-02-01

10
papers

317
citations

1478505

6
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

398
citing authors

#	ARTICLE	IF	CITATIONS
1	Adapting treatment length to opioid-dependent individuals'™ needs and preferences: a 2-year follow-up to a 1-year study of extended-release naltrexone. <i>Addiction</i> , 2021, 116, 2084.	3.3	5
2	Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial. <i>American Journal on Addictions</i> , 2021, 30, 453-460.	1.4	2
3	"Not at all what I had expected"™: Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study. <i>Journal of Substance Abuse Treatment</i> , 2021, , 108667.	2.8	7
4	Discrepancy in Ratings of Shared Decision Making Between Patients and Health Professionals: A Cross Sectional Study in Mental Health Care. <i>Frontiers in Psychology</i> , 2020, 11, 443.	2.1	9
5	Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial. <i>European Addiction Research</i> , 2019, 25, 303-309.	2.4	7
6	Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone. <i>JAMA Psychiatry</i> , 2019, 76, 127.	11.0	44
7	Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial. <i>Addiction</i> , 2018, 113, 1840-1849.	3.3	20
8	Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence. <i>JAMA Psychiatry</i> , 2017, 74, 1197.	11.0	200
9	Interest in Extended Release Naltrexone among Opioid Users. <i>European Addiction Research</i> , 2016, 22, 301-305.	2.4	5
10	Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX). <i>BMC Pharmacology & Toxicology</i> , 2016, 17, 18.	2.4	18